CD14 and non-small cell lung carcinoma: These findings are further in line with a clinical case report in which it was shown that a stage III NSCLC patient undergoing durvalumab treatment (anti-PD-L1 mAb) showed a reduced number of circulating CD14+ and CD124+ myeloid cells (22).